

Addendum

Addendum: Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma

Andy Karabajakian¹, Thibaut Garrivier², Carole Crozes³, Nicolas Gadot⁴, Jean-Yves Blay¹, Frédéric Bérard⁵, Philippe Céruse⁶, Philippe Zrounba⁷, Pierre Saintigny⁴, Charles Mastier² and Jérôme Fayette¹

¹Department of Medical Oncology, Centre Léon Bérard, Lyon, France

²Department of Radiology, Centre Léon Bérard, Lyon, France

³Department of Pathology, Centre Léon Bérard, Lyon, France

⁴Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France

⁵Department of Allergology and Clinical Immunology, CHU Lyon-Sud, Pierre-Bénite, France

⁶Department of Head and Neck Surgery, Hôpital Universitaire de la Croix-Rousse, Lyon, France

⁷Department of Head and Neck Surgery, Centre Léon Bérard, Lyon, France

Published: December 06, 2022

Copyright: ©2022 Karabajakian et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Patient consent was obtained from the patient. This study was approved by the ethical review board of Centre Léon-Bérard.

Original article: Oncotarget. 2020; 11:1618–1628. <https://doi.org/10.18632/oncotarget.27563>